Todd Tushla
Vice President, Investor Relations
Replay available
Neurocrine Biosciences, Inc. (NBIX) Q2 2026 Earnings Call
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) Q2 2026 earnings conference call, held 2026-07-30. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Kyle Gano
Chief Executive Officer
Matt Abernethy
Chief Financial Officer
Eric Benevich
Chief Commercial Officer
Sanjay Keswani
Chief Medical Officer
Paul Matisse
Analyst, Stiefel
Phil Nadeau
Analyst, Petey Cowan
Tazeen Ahmad
Analyst, Bank of America
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Neurocrine Biosciences, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.051 -- 00:00:05.552 Hello and welcome everyone joining today's Neurocrine Biosciences Reports 00:00:05.552 -- 00:00:09.293 Q2 2026 earnings call. 00:00:09.293 -- 00:00:13.554 At this time, all participants are in a listen-only mode. 00:00:13.554 -- 00:00:18.655 Later, you will have the opportunity to ask questions during the question and answer 00:00:18.655 -- 00:00:23.896 session. To register to ask a question at any time, please press 00:00:23.896 -- 00:00:27.777 star 1 on your telephone keypad. Please 00:00:27.777 -- 00:00:32.939 note this call is being recorded. Todd Tushla, Vice President of Investor 00:00:32.939 -- 00:00:34.680 Relations. 00:00:34.680 -- 00:00:36.742 Please go ahead. Happy Thursday, everyone. 00:00:36.742 -- 00:00:42.305 Welcome to Neurocrine Biosciences' second quarter 2026 earnings call. 00:00:49.285 -- 00:00:53.969 With me today on the call are Kyle Gano, Chief Executive Officer, Matt Abernethy, Chief 00:00:53.969 -- 00:00:59.113 Financial Officer, Eric Benevich, Chief Commercial Officer, Sanjay Keswani, Chief Medical 00:00:59.113 -- 00:01:04.156 Officer, and in his well-deserved new role as Chief Business Officer, Samir 00:01:04.156 -- 00:01:08.240 Sadanti. During today's call, we will be making forward-looking statements. 00:01:08.240 -- 00:01:12.343 These statements are subject to certain risks and uncertainties, and our actual results 00:01:12.343 -- 00:01:17.046 may differ materially. I encourage you to review the risk factors discussed in our latest 00:01:17.046 -- 00:01:19.005 SEC filings. 00:01:19.005 -- 00:01:23.188 In addition, some of the information discussed today includes non-GAAP financial measures 00:01:23.188 -- 00:01:25.629 that have not been calculated in accordance with U.S. 00:01:25.629 -- 00:01:30.832 GA...